New combo shows promise for tough kidney cancers
NCT ID NCT03635892
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests two drugs, nivolumab and cabozantinib, together in 60 people with advanced or metastatic non-clear cell kidney cancer. The goal is to see how well the combination shrinks tumors. Participants take cabozantinib daily and receive nivolumab infusions every two weeks until the disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab and cabozantinib
- What this could lead to
- If successful, this combination could offer a new treatment option for people with rare types of advanced kidney cancer that are hard to treat.
- What could go wrong
- This is a small, early-phase trial with only 60 participants. The drugs may cause significant side effects, and the cancer may still progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NON-CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for rare kidney cancer: drug combo shows promise in late-stage trial
- 8,000 kidney tumor samples collected to unlock cancer clues
- Experimental immune cell therapy targets Hard-to-Treat cancers
- New combo shows promise for rare kidney cancers
- Scientists track Cancer's diet in real time during surgery
- Supercharged immune cells take on advanced kidney and bladder tumors